Advertisement

Advertisement
Immunotherapy
Gynecologic Cancers

KEYNOTE-158: Pembrolizumab in Previously Treated Advanced Cervical Cancer

As reported in the Journal of Clinical Oncology by Chung et al, the phase II KEYNOTE-158 trial showed activity of pembrolizumab in previously treated...

Prostate Cancer

Enzalutamide Plus ADT Extends Progression-Free Survival in Metastatic Hormone-Sensitive Prostate Cancer

Adding enzalutamide to androgen-deprivation therapy (ADT) significantly prolonged radiographic progression-free survival in men with metastatic hormone-sensitive...

Breast Cancer

Addition of Radiotherapy After Breast-Conserving Surgery Based on Level of Tumor-Infiltrating Lymphocytes

In a long-term follow-up of the Swedish Breast Cancer Group 91 Radiotherapy trial reported in the Journal of Clinical Oncology, Kovács et al...


Advertisement
Immunotherapy

The Future of Immunotherapy: Building on Checkpoint Blockade

The emergence of anticancer agents that block immune checkpoints has transformed the field of oncology, leading to durable responses and improvements in overall survival...

Lymphoma
Genomics/Genetics

Addition of Bortezomib to R-CHOP in DLBCL Subtypes Identified With Gene-Expression Profiling

In the phase III REMoDL-B trial reported in The Lancet Oncology, Davies et al found that the addition of bortezomib to standard R-CHOP...

Advertisement




More Top Stories

Lung Cancer
Immunotherapy

Jyoti D. Patel, MD, on Stage III Non–Small Cell Lung Cancer: A Look at New Systemic Treatments

Bladder Cancer

Antibody-Drug Conjugate Shows Activity in Heavily Pretreated Bladder Cancer

PRELIMINARY EVIDENCE suggests that the antibody-drug conjugate sacituzumab govitecan is active in patients previously treated with chemotherapy or checkpoint inhibitor therapy for metastatic urothelial cancer. These results from a phase I/II basket study of this agent were presented at the 2019...

Advertisement

Study Finds Medicaid Reimbursement for Radiation Therapy Varies Widely State-to-State

A new study found wide state-to-state variations in Medicaid reimbursements to physicians who treat patients with cancer with radiation therapies. These differences could compound existing disparities in access to health care in rural communities, which tend to have higher Medicaid...

Lung Cancer
Immunotherapy

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing

Hematologic Malignancies
Immunotherapy

Allogeneic Hematopoietic Cell Transplantation and Cell Therapy

As part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several studies of allogeneic hematopoietic cell transplantation (allo-HCT) and cellular therapy, as used in myelodysplastic syndromes (MDS),...

Help Patients Do More to Cope With Cancer-Related Pain

RELIEVING PAIN is an important part of cancer care, and each patient experiences pain differently. Give your patients the information and tools they need to understand and manage their pain. ASCO Answers offers two helpful products on managing cancer-related pain: a one-page fact sheet or an...

Complementary and Alternative Medicine Use in Patients With Cancer

In a recent study focusing on patients with cancer and cancer survivors, one-third of patient participants reported use of complementary and alternative medicines such as meditation, yoga, acupuncture, herbal medicine, and supplements. These findings were published by Sanford et al in JAMA...

Kidney Cancer
Immunotherapy

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Results From the NIVOREN GETUG-AFU 26 Study on Nivolumab

Hematologic Malignancies
Multiple Myeloma

FDA Warning: Investigational Use of Venetoclax in Multiple Myeloma

On March 21, 2019, the U.S. Food and Drug Administration (FDA) posted a safety statement on the investigational use of venetoclax in multiple myeloma. The statement alerts health-care professionals and patients about the suspension of the BELLINI trial (ClinicalTrials.gov identifier NCT02755597)...

Advertisement

KEYNOTE-158: Pembrolizumab in Previously Treated Advanced Cervical Cancer

As reported in the Journal of Clinical Oncology by Chung et al, the phase II KEYNOTE-158 trial showed activity of pembrolizumab in previously treated programmed cell death ligand 1 (PD-L1)-positive advanced cervical cancer. The study supported the 2018 accelerated approval of pembrolizumab in this...